Skip to content

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02133989
Acronym
CRECAS
Enrollment
86
Registered
2014-05-08
Start date
2014-06-30
Completion date
2017-12-31
Last updated
2017-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Stenosis

Keywords

Carotid stenosis, Stenting, Clopidogrel resistance, Stroke, ischemic

Brief summary

The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior than clopidogrel in terms of post-stent ischemic lesions in these patients without serious complications.

Interventions

DRUGTiclopidine + Ginko biloba

ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily

DRUGClopidogrel

clopidogrel bisulfate 97.875mg(75mg as clopidogrel)

Sponsors

Yuyu Pharma, Inc.
CollaboratorINDUSTRY
Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for stent implantation due to carotid stenosis * Patients resistant to clopidogrel defined by platelet inhibition rate \<20% measured by Verify Now before carotid stenting * Patients with informed consent

Exclusion criteria

* Antiplatelet therapy other than aspirin, clopidogrel, or ticlopidine * Unable to perform MRI scans * Patients with hematologic abnormalities including neutrophil \<1500/ul, platelet \<100,000/uL, or AST/ALT \>120 U/L * Unsuitable for participation

Design outcomes

Primary

MeasureTime frameDescription
New ischemic lesion on diffusion-weighted imaging (DWI)within 24 hours after carotid stentingPresence of new ischemic lesion in the ipsilesioinal hemisphere on DWI after carotid stening

Secondary

MeasureTime frameDescription
Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD)within 24 hours after carotid stenting
Ischemic stroke or transient ischemic attack (TIA)within 30 days after carotid stenting
Change of clopidogrel resistance1 day after carotid stentingChange of clopidogrel resistance measured by Verify now (P2Y12)
Number and Volume of new ischemic lesions on DWIwithin 24 hours after carotid stenting
Mycocardial infarctionwithin 30 days after carotid stenting
Deathwithin 30 days after carotid stenting
Hematological abnormalitieswithin 30 days after carotid stentingNeutrophil \<1500/uL Platelet \<100,000/uL AST or ALT \>120 U/L
Pucture site hematomawithin 30 days after carotid stenting

Countries

South Korea

Contacts

Primary ContactOh Young Bang, MD
neuroboy50@naver.com82-2-3410-3599
Backup ContactSuk Jae Kim, MD
sukjae.kim@gmail.com82-2-3410-1895

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026